EMEA-001006-PIP05-18-M01
Key facts
| Invented name |
|
| Active substance |
nintedanib
|
| Therapeutic area |
|
| Decision number |
P/0438/2021
|
| PIP number |
EMEA-001006-PIP05-18-M01
|
| Pharmaceutical form(s) |
Capsule, soft
|
| Condition(s) / indication(s) |
Treatment of fibrosing Interstitial Lung Diseases (ILD)
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Boehringer Ingelheim International GmbH
E-mail: COMMSPaediatrics@boehringer-ingelheim.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-001006-PIP05-18-M01
|
| Compliance opinion date |
22/07/2022
|
| Compliance outcome |
positive
|